Journal of Infection and Public Health
Volume 3, Issue 2 , Pages 47-53 , 2010

Prevention or treatment: The benefits of Trichomonas vaginalis vaccine

  • Sarah L. Cudmore
    • ,
  • Gary E. Garber

      Affiliations

    • Corresponding Author InformationCorresponding author at: Division of Infectious Diseases, Ottawa Hospital, General Campus, 501 Smyth Rd., Ottawa, ON, Canada K1H 8L6. Tel.: +1 613 737 8173; fax: +1 613 737 8099.

Received 15 July 2009 ,Revised 20 January 2010 ,Accepted 25 January 2010.

References 

  1. World Bank. World development report: investing in health. Washington: World Bank; 1993.
  2. WHO . Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates. Geneva: World Health Organization; 1999;
  3. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–317
  4. Zigas V. An evaluation of trichomoniasis in two ethnic groups in Papua New Guinea. Sex Transm Dis. 1977;4:63–65
  5. Bowden FJ, Paterson BA, Mein J, Savage J, Fairley CK, Garland SM, et al. Estimating the prevalence of Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorroheae in indigenous women in Northern Australia. Sex Transm Inf. 1999;75:431–434
  6. Wilcox RR. Epidemiological aspects of trichomoniasis. Br J Vener Dis. 1960;36:167–174
  7. Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, et al. Trichomonas vaginalis associated with low birth weight and pre-term delivery. Sex Transm Dis. 1997;24:353–360
  8. Hobbs MM, Kazembe P, Reed AW, Miller WC, Nkata E, Zimba D, et al. Trichomonas vaginalis as a cause of urethritis among Malawian men. Sex Transm Dis. 1999;26:381–387
  9. Saxena SB, Jenkins RR. Prevalence of Trichomonas vaginalis in men at high risk for sexually transmitted diseases. Sex Trans Dis. 1991;18:138–142
  10. Weston TE, Nicol CS. Natural history of trichomonal infection in men. Br J Vener Dis. 1963;39:251–257
  11. Lossick J. Treatment of sexually transmitted diseases. Rev Inf Dis. 1990;12(Suppl. 6):S665–S681
  12. Cudmore SL, Delgaty KL, Hayward-McClelland SF, Petrin DP, Garber GE. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev. 2004;17(4):783–793
  13. Schmidt G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46:545–549
  14. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209–4210
  15. Price MA, Stewart SR, Miller WC, Behets F, Dow WH, Martinson FE, et al. The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr. 2006;43:202–209
  16. KissingerP , Schmidt N, Mohammed H, Leichliter JS, Gift TL, Meadors B, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33:445–450
  17. Cwikel JG, Lazer T, Press F, Lazer S. Sexually transmissible infection among female sex workers: an international review with an emphasis on hard-to-access populations. Sexual Health. 2008;5:9–16
  18. Cwikel JG. A textbook of social epidemiology—strategies for social health activism. New York: Columbia University Press; 2006;
  19. Bowden FJ, Garnett GR. Trichomonas vaginalis epidemiology: parameterizing and analyzing a model of treatment interventions. Sex Transm Dis. 2000;76:248–256
  20. Rogers A, Meundi A, Amma A, Rao A, Shetty P, Antony A, et al. HIV-related knowledge, attitudes, perceived benefits, and risks of HIV testing among pregnant women in rural southern India. AIDS Patient Care STDs. 2006;20(11):803–811
  21. Sturm AW, Wilkinson D, Ndovela N, Bowen S, Connolly C. Pregnant women as a reservoir of undetected sexually transmitted disease in rural South Africa: implications for disease control. Am J Public Health. 1998;88:1243–1245
  22. Peterman TA, Tian LH, Metcalf CA, Satterwhite CL, Malotte CK, DeAugistine N, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145:564–572
  23. McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, Kairie J, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Inf Dis. 2007;195:698–702
  24. Kissinger P, Secor WE, Leichliter JS, Clark RA, Schmidt N, Curtin E, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Inf Dis. 2008;46:994–999
  25. Ter Meulen J, Mgaya HN, Chang-Claude J, Luande J, Mtiro H, Mhina M, et al. Risk factors for HIV infection in gynaecological inpatients in Dar es Salaam, Tanazania, 1988–1990. East Afr J. 1992;69:688–692
  26. Kreiss J, Willerford DM, Hensel M, Emonyi W, Plummmer F, Ndinya-Achola J, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Inf Dis. 1994;170:1597–1601
  27. Moodley P, Connolly C, Sturm AW. Interrelationships between human immunodeficiency virus type 1, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Inf Dis. 2002;185:69–73
  28. Fouts AC, Kraus SJ. Trichomonas vaginalis: reevaluation of its clinical presentation and laboratory diagnosis. J Inf Dis. 1980;141:137–143
  29. Draper D, Donohoe W, Mortimer M, Heine RP. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Inf Dis. 1998;178:815–818
  30. LevineWC , Pope V, Boomhar A, Tambe P, Lewis JS, Zaidi AA, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Inf Dis. 1998;177:167–174
  31. Sardana S, Sodhani P, Agarwal SS, Sehgal A, Roy M, Singh V. Epidemiologic analysis of Trichomonas vaginalis infection in inflammatory smears. Acta Cytol. 1994;38:693–697
  32. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Inf Immun. 2005;73(7):4155–4160
  33. BonDurant RH, Honigberg BM. Trichomonads of veterinary importance. Parasitic Protozoa. vol. 9. New York, NY: Academic Press; 1994;p. 111–188
  34. Silva Filho FC, de Souza W. The interaction of Trichomonas vaginalis and Tritrichomonas foetus with epithelial cells in vitro. Cell Struct Funct. 1988;13:301–310
  35. Burgess DE, Knoblock KF, Daugherty T, Robertson NP. Cytotoxic and hemolytic effects of Tritrichomonas foetus on mammalian cells. Infect Immun. 1990;58(11):3827–3832
  36. Aburel E, Zervos G, Titea V, Pana S. Immunological and clinical investigations into vaginal trichomoniasis. Rum Med Rev. 1963;7:13–19
  37. Garber GE, Proctor EM, Bowie WR. Immunogenic proteins of Trichomonas vaginalis as demonstrated by the immunoblot technique. Infect Immun. 1986;51:253–263
  38. Addis MA, Rappelli P, de Andrade AMP, Rita FM, Colombo M, Capuccinelli P, et al. Identification of Trichomonas vaginalis α-actinin as the most common antigen recognized by the sera of women exposed to the parasite. J Infect Dis. 1999;180:1727–1730
  39. Davis-Hayman SR, Shah PH, Finley RW, Meade JC, Lushbaugh WB. Antigenicity of Trichomonas vaginalis heat-shock proteins in human infections. Parasitol Res. 2000;86:115–120
  40. Hayward-McClelland SF, Delgaty KL, Garber GE. Animal models of Trichomonas vaginalis infection with special emphasis on the intravaginal mouse model. Handbook of animal models of infection. New York, NY: Academic Press; 1999;p. 839–50

PII: S1876-0341(10)00004-3

doi: 10.1016/j.jiph.2010.01.003

Journal of Infection and Public Health
Volume 3, Issue 2 , Pages 47-53 , 2010

Article Tools